Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.650 -0.030 (-0.45%)

Streaming Delayed Price Updated: 11:32 AM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

30 31 Next >

Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript ↗

August 04, 2023

CMPS earnings call for the period ending June 30, 2023.

Via The Motley Fool

COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business' ↗

August 03, 2023

Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows:

Via Benzinga

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗

July 30, 2023

All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:

Via Talk Markets

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock ↗

July 28, 2023

For biotechs developing psychedelic therapies, good news comes in many forms.

Via The Motley Fool

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

July 26, 2023

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

Via FinancialNewsMedia

Compass' Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows ↗

July 25, 2023

UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the...

Via Benzinga

AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies

July 25, 2023

By Rachael Green, Benzinga

Via TheNewswire.com

AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies

July 25, 2023

--News Direct--

Via News Direct

Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More ↗

July 24, 2023

Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...

Via Benzinga

AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies ↗

July 24, 2023

The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments.

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗

July 23, 2023

The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...

Via Talk Markets

Jim Cramer Says It's Time To Buy This Financial Services Stock Down 32% YTD ↗

July 21, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN) is not even as good as Danaher Corporation (NYSE: DHR).

Via Benzinga

Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies' ↗

July 18, 2023

COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.)

Via Benzinga

Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗

July 14, 2023

Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.

Via Talk Markets

Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 12, 2023

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.

Via Benzinga

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

Top 5 Health Care Stocks That May Collapse This Quarter ↗

July 10, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Psychedelic Stocks Jumped 10% Last Week ↗

July 09, 2023

The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly

Via Talk Markets

Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 07, 2023

Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per...

Via Benzinga

COMPASS Pathways Projects 2027 Commercialization Timeline For Psilocybin Therapy ↗

July 07, 2023

With timelines for the submission of approval for MDMA-assisted therapy becoming more clear, COMPASS Pathways (NASDAQ: CMPS) has provided their o

Via Benzinga

Alibaba, Kura Sushi USA And Other Big Stocks Moving Higher On Friday ↗

July 07, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures ↗

July 06, 2023

The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by...

Via Benzinga

COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital ↗

July 05, 2023

Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist

Via Benzinga

Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗

July 01, 2023

Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...

Via Talk Markets

Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? ↗

July 01, 2023

Wall Street might have the timing wrong, but their hopes aren't misplaced.

Via The Motley Fool

The 3 Best Psychedelic Stocks to Buy Now ↗

June 29, 2023

Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside.

Via InvestorPlace

Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗

June 17, 2023

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.

Via Talk Markets

Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗

June 10, 2023

Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index

Via Talk Markets

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.